Biota Receives $4.2m R&D Tax Credit

Biota Receives $4.2m R&D Tax Credit

ID: 200338

(firmenpresse) - MELBOURNE, AUSTRALIA -- (Marketwire) -- 11/07/12 -- In addition to the disclosure in the 2012 Annual Report, Biota Holdings limited (ASX: BTA) today announced that it received $4.2m in respect to the Australian Research and Development tax incentive ("Offset "), following submission of its 2012 Australian tax return.

As a result, Biota's cash position increased by $4.2m and will be recognized as a tax credit in the income statement in the December quarter financial reports.

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has a well advanced program for human rhinovirus (HRV) infection with a completed Phase IIb study in asthmatic subjects.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product lnavir®, is marketed in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.
Inavir® is registered to Daiichi Sankyo.



Peter Cook
T: +61 3 9915 3720
Damian Lismore
T: +61 3 9915 3721

Nerida Mossop
Hinton & Associates
T: +61 3 9600 1979 / M: +61 437 361 433
Felicity Williams
Hinton & Associates
T: +61 3 9600 1979 / M: +61 416 770 012

Hershel Berry
Blueprint Life Science Group
M: +1 415 505 3749




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Acura Pharmaceuticals Announces Third Quarter 2012 Financial Results Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2012 Financial Results
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 07.11.2012 - 10:30 Uhr
Sprache: Deutsch
News-ID 200338
Anzahl Zeichen: 0

contact information:
Town:

MELBOURNE, AUSTRALIA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 214 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Biota Receives $4.2m R&D Tax Credit"
steht unter der journalistisch-redaktionellen Verantwortung von

Biota (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Biota and Nabi Announce Revised Merger Terms ...

MELBOURNE, AUSTRALIA -- (Marketwire) -- 09/18/12 -- Biota Holdings Limited (ASX: BTA) today announced revised terms for the proposed merger with Nabi Biopharmaceuticals.The movement in the Biota share price since the merger was announced in April 20 ...

Alle Meldungen von Biota



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z